https://nova.newcastle.edu.au/vital/access/manager/Index ${session.getAttribute("locale")} 5 https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:46788 Wed 30 Nov 2022 13:21:42 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45277 0.14). Conclusion: In this secondary analysis of a primary efficacy study, PD was a common comorbidity among those with MDD, but was not a significant predictor of functional outcomes. This study adds to the limited literature on PD in randomized controlled trials for MDD.]]> Wed 26 Oct 2022 17:13:15 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45043 n = 717) were administered the Structured Clinical Interview for DSM-IV (SCID-I/NP and SCID-II) and the World Health Organisation Quality of Life scale (WHOQOL-BREF). Weight and height were measured and lifestyle and demographic factors were self-reported. Logistic regression models (odds ratios with 95% confidence intervals) were undertaken to investigate associations among groups (mental state disorders, co-occurring mental state disorders with PD, and controls) and the WHOQOL-BREF domains (physical, psychological, social, and environmental health) while testing for potential confounding. Results: Results indicated that mental state disorders were associated with increased risk of low quality of life in physical, psychological, social, but not environmental domains, compared to controls. This risk was increased among women with co-occurring PD across all domains compared to both controls and those with mental state disorders. Conclusion: These findings add evidence suggesting poor quality of life is experienced by those with mental state disorders, and that this is worsened by the experience of co-occurring PD.]]> Wed 26 Oct 2022 12:00:30 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54880 Wed 20 Mar 2024 13:17:37 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:43158 Wed 14 Jun 2023 09:50:31 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:22895 Wed 11 Apr 2018 09:57:00 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36597 Wed 10 Jun 2020 15:12:41 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53737 Wed 10 Jan 2024 11:31:34 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39815 I² statistic. This systematic review was registered with PROSPERO (CRD42018089279) and the protocol is published. Results: The search yielded 11,640 studies. Subsequent to removing duplicates, 9657 studies were screened at title and abstract stage and 1456 were assessed at full-text stage. Eighteen studies met criteria for inclusion in this review. Meta-analysis did not reveal a significant difference between groups for treatment outcome (standardised mean difference 0.22 [-0.09, 0.54]; I²: 69%, p=0.17) and remission (risk ratio 0.84 [0.64, 1.11]; I²: 51%, p=0.22). Limitations: This review was limited by lack of studies on bipolar disorder. Conclusion: PD comorbidity does not appear to affect treatment efficacy of pharmacological interventions for adults with mood disorders.]]> Wed 10 Aug 2022 13:16:51 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53619 Wed 07 Feb 2024 14:40:08 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50157 Wed 05 Jul 2023 15:21:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50150 50% at baseline). Untargeted gas chromatography–mass spectrometry analysis was performed to analyse baseline levels of 68 serum metabolites. Of the nine metabolites that differentiated placebo and NAC groups, five were amino acids with lower levels in the NAC responder group compared with the NAC non-responders. Further analysis generated a predictive model of MADRS improvement including glycine, norleucine, threonine, proline, phenylalanine, tyrosine, glutamic acid, lysine and leucine (R2 = 0.853; adjusted R2 = 0.733). This prediction model predicted 85% of the variance in MADRS outcome after adjunctive treatment with NAC. BD participants with lower serum levels of free amino acids at baseline may be more likely to respond to adjunctive treatment with NAC.]]> Wed 05 Jul 2023 14:11:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:38155 Wed 04 Aug 2021 18:23:45 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39853 Tue 26 Jul 2022 10:28:34 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51126 Tue 22 Aug 2023 15:51:43 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51127 Tue 22 Aug 2023 15:51:17 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51427 Tue 05 Sep 2023 17:47:47 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52092 Thu 28 Sep 2023 14:29:23 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:50837 Thu 17 Aug 2023 11:53:14 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:54278 Thu 15 Feb 2024 14:38:24 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:26171 Sat 24 Mar 2018 07:30:06 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49523 Sat 20 May 2023 12:39:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44764 Mon 24 Oct 2022 08:49:36 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:27031 Mon 23 Sep 2019 12:39:49 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:39177 n = 133). Participants received 16 weeks adjunctive treatment of either placebo or N-acetylcysteine-alone or a combination of mitochondrial-enhancing nutraceuticals including N-acetylcysteine (combination treatment). Participants were followed up 4 weeks post-treatment discontinuation (Week 20). Diet was assessed by the Cancer Council Victoria Dietary Questionnaire for Epidemiological Studies, Version 2, converted into an Australian Recommended Food Score to measure diet quality, and energy-adjusted dietary inflammatory index score to measure inflammatory potential of diet. Body mass index was also measured. Generalised estimating equation models were used to assess whether diet quality, energy-adjusted dietary inflammatory index score and/or body mass index were predictors of response to significant outcomes of the primary trial: depression symptoms, clinician-rated improvement and functioning measures. Results: In participants taking combination treatment compared to placebo, change in depression scores was not predicted by Australian Recommended Food Score, dietary inflammatory index or body mass index scores. However, participants with better diet quality (Australian Recommended Food Score) reported reduced general depression and bipolar depression symptoms (p = 0.01 and p = 0.03, respectively) and greater clinician-rated improvement (p = 0.02) irrespective of treatment and time. Participants who had a more anti-inflammatory dietary inflammatory index had less impairment in functioning (p = 0.01). Combination treatment may attenuate the adverse effects of pro-inflammatory diet (p = 0.03) on functioning. Participants with lower body mass index who received combination treatment (p = 0.02) or N-acetylcysteine (p = 0.02) showed greater clinician-rated improvement. Conclusion: These data support a possible association between diet (quality and inflammatory potential), body mass index and response to treatment for bipolar depression in the context of a nutraceutical trial. The results should be interpreted cautiously because of limitations, including numerous null findings, modest sample size and being secondary analyses.]]> Mon 23 May 2022 14:53:36 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:49563 0.05). After adjustment for demographic differences, participants who smoked had lower craving [b (SE) = −1.1 (0.5), P = 0.021] and were less likely to report psychotic symptoms [b (SE) = −1.8 (0.7), P = 0.013] or antidepressant use [b (SE) = −1.1 (0.5), P = 0.022]. Discussion and Conclusions: Smoking crystalline methamphetamine is associated with a younger less marginalised demographic profile than injecting methamphetamine, but a similarly severe clinical profile.]]> Mon 22 May 2023 09:20:09 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:43425 P < .001). Conclusions: Noting the strong association between depression and other chronic diseases in our sample of older adults from 6 LMICs, additional vigilance and screening through informal and formal health care systems would help to decrease the impact of comorbidity on the health and well-being of older populations.]]> Mon 19 Sep 2022 08:40:18 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:53779 Mon 15 Jan 2024 10:17:11 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:52335 Mon 09 Oct 2023 14:50:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51396 Mon 04 Sep 2023 14:43:02 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51391 Mon 04 Sep 2023 13:47:42 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:45466 n = 114 participants with completed cognitive outcomes at follow up were included in this analysis. Using the Cogstate Brief Battery, the following cognitive outcomes were assessed: psychomotor function, attention, visual learning and memory (visual and working). Subgroup analyses investigated whether baseline clinical parameters (baseline cognitive functioning, illness severity and duration, depressive symptoms) moderated the relationship between mangosteen pericarp extract intervention and change in cognitive outcomes. Results: There were no significant between-group changes in any cognitive outcomes assessed. Subgroup analysis based on baseline cognition and clinical characteristics did not reveal any significant between-group difference in change. Conclusions: Mangosteen pericarp extract did not affect cognitive outcomes in people with schizophrenia. Further investigation regarding optimal dosing strategies for mangosteen interventions and the testing of additional cognitive domains may be warranted.]]> Fri 28 Oct 2022 14:45:19 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:42120 Fri 26 Aug 2022 10:32:20 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51700 Fri 15 Sep 2023 10:39:15 AEST ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:44403 Fri 14 Oct 2022 08:52:12 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:36378 Fri 03 Apr 2020 16:17:31 AEDT ]]> https://nova.newcastle.edu.au/vital/access/manager/Repository/uon:51362 Fri 01 Sep 2023 13:44:30 AEST ]]>